ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
Rhea-AI Summary
ALX Oncology (NASDAQ: ALXO) has announced a webcast event scheduled for May 20, 2025, focusing on ALX2004, their novel antibody-drug conjugate (ADC). The event will showcase ALX2004's mechanism of action, preclinical data, and clinical development strategy following FDA's IND clearance earlier this year.
ALX2004, developed in-house using the company's proprietary topoisomerase I inhibitor payload platform, is designed to target EGFR-expressing tumors. The presentation will feature key executives including CEO Jason Lettmann, CMO Alan Sandler, and VP of Antibody Technologies Marija Vrljic, who will discuss planned clinical progress and updates.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ALXO gained 10.52%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company’s potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the novel mechanism of action, preclinical data and clinical development strategy for ALX2004 following clearance of the Investigational New Drug application from the U.S. Food and Drug Administration earlier this year.
ALX2004 was fully designed and developed in-house by ALX Oncology scientists. By leveraging the Company’s proprietary, highly differentiated topoisomerase I inhibitor payload platform, ALX2004 optimizes ADC-based mechanisms of anti-tumor activity and is designed to improve outcomes in patients with EGFR-expressing tumors.
ALX Oncology leadership Jason Lettmann, Chief Executive Officer, Alan Sandler, Chief Medical Officer and Marija Vrljic, Vice President of Antibody Technologies, will discuss planned clinical progress and updates for ALX2004 during the virtual webcast event.
ALX2004 Webcast Information
The virtual event will be webcast live and a replay will be available after the event by visiting the "Investors" section of ALX Oncology’s website and selecting "Events and Presentations."
Date & Time: Tuesday, May 20, 2025, 8:00 a.m. PT/11:00 a.m. ET
Webcast Access: https://edge.media-server.com/mmc/p/ohnn53h5
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Audra Friis, Sam Brown Healthcare Communications
audrafriis@sambrown.com
(917) 519-9577
FAQ
What is ALX2004 and how does it work?
When is ALX Oncology (ALXO) hosting its R&D webcast for ALX2004?
What is the current development status of ALX2004?
Who will be presenting at the ALX Oncology webcast event?
